SNSE vs SPRY

Sensei Biotherapeutics, Inc. vs ARS Pharmaceuticals, Inc. — Valuation Comparison 2026

SNSE

Pharmaceutical Preparations
Sensei Biotherapeutics, Inc.
Quality
3.7
out of 10
Value Trap
36
LOW
Price
$21.14
Last close
Models
5/13
Active
VS

SPRY

Pharmaceutical Preparations
ARS Pharmaceuticals, Inc.
Quality
4.7
out of 10
Value Trap
24
SAFE
Price
$9.07
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType SNSE Fair ValueSNSE Upside SPRY Fair ValueSPRY Upside
Bayesian DCF Intrinsic $66.45 +214.3% $1.86 -79.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.33 -95.1% $1.53 -83.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SNSE vs SPRY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SNSE vs SPRY — Which Stock Is More Undervalued?

SPRY scores higher with a 4.7/10 quality rating vs SNSE's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sensei Biotherapeutics, Inc. (SNSE) and ARS Pharmaceuticals, Inc. (SPRY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SNSE currently trades at $21.14 with a QOC of 3.7/10, while SPRY trades at $9.07 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).